Selective glycoimmuno-targeting for cancer therapy

Informazioni relative al progetto

SweetAim

ID dell’accordo di sovvenzione: 716220

DOI

10.3030/716220

Progetto chiuso

Data della firma CE 28 Novembre 2016

Data di avvio 1 Dicembre 2016

Data di completamento 30 Novembre 2022

Finanziato da

• EXCELLENT SCIENCE - European Research Council (ERC)

Costo totale

€ 1 479 995,00

Contributo UE

€ 1 479 995,00

Coordinato da

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 4 - SweetAim (Selective glycoimmuno-targeting for cancer therapy)

Periodo di rendicontazione: 2021-06-01 al 2022-11-30

Sintesi del contesto e degli obiettivi generali del progetto

Cancer is a leading cause of death worldwide and new therapies are still needed. The primary objective of this proposal is to design a novel cancer therapeutic approach and to address the challenges faced by the study of carbohydrates immune recognition. It is based on findings that some tumor-associated carbohydrates can be targeted for cancer therapy. We investigated the potential of robust effective targeting of tumor-carbohydrates with antibodies both in vitro and in vivo. This research is has provided tools for designing novel therapeutics, imaging and diagnostics for cancer and for other chronic inflammation-related diseases, that are very important to reduce cancer burden for the benefit of society.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

We investigated carbohydrates as targets for antibody therapy in cancer. We explored the different factors that affect carbohydrate binding and recognition and developed several methods to improve antibody recognition and cancer killing potential both through passive therapy, as well as through active cancer vaccine design.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

We have already published fifteen papers and submitted 8 patents related to the use of antibodies for cancer diagnostics and therapy.

072120-nutri-red-meat-cancer-risk-low-resolution.jpg